Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical perspectives in Crohn's disease. Serologic and prognostic biomarkers: who, when, and how?

Reviews in gastroenterological disorders - 1 Jan 2007

Dubinsky Marla C

Abstract excerpt

The introduction of anti-tumor necrosis factor-a therapies has significantly expanded the armamentarium for patients with inflammatory bowel disease (IBD). Clinical experience has shown that not all patients respond to therapies in this class, which emphasizes the hypothesis that there are different pathways involved in the inflammatory cascade characteristic of the spectrum of IBD phenotypes. The broadening of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibody Formation
Share to Biomarkers
Share to Crohn Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Phenotype

Share to Prognosis

Share to Tumor Necrosis Factor-alpha

Source

Identifiers

PMID: 17392637

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical perspectives in Crohn's disease. Serologic and prognostic biomarkers: who, when, and how?PMID 17392637Read ↗

Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.Semantic proximity Read ↗

The use of prognostic factors in inflammatory bowel diseases.Semantic proximity Read ↗

Molecular diagnosis and classification of inflammatory bowel disease.Semantic proximity Read ↗

Molecular Profiling of Inflammatory Bowel Disease: Is It Ready for Use in Clinical Decision-Making?Semantic proximity Read ↗

Have genomic discoveries in inflammatory bowel disease translated into clinical progress?Semantic proximity Read ↗

Time to Revisit Disease Classification in Inflammatory Bowel Disease: Is the Current Classification of Inflammatory Bowel Disease Good Enough for Optimal Clinical Management?Semantic proximity Read ↗

Emerging Biomarkers for the Diagnosis and Monitoring of Inflammatory Bowel Diseases.Semantic proximity Read ↗

Recent advances in understanding and managing Crohn’s diseaseSemantic proximity Read ↗

Evolving paradigms in the pathogenesis of IBD.Semantic proximity Read ↗

Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.Semantic proximity Read ↗

Biomarkers in Search of Precision Medicine in IBD.Semantic proximity Read ↗

Classification of inflammatory bowel disease: the old and the new.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.